Latest Commercialization Strategy News

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Lithium Plus Minerals reports key regulatory and environmental milestones for its Lei Lithium Development Project, progressing towards a near-term direct shipped ore operation backed by a strategic partnership with Canmax Technologies.

Green Critical Minerals has commissioned its first VHD Graphite production module and secured $7 million to drive commercialisation, while its McIntosh Project delivers robust economic metrics.

Immuron Limited reports a robust 49% increase in FY25 global sales of its immune supplement Travelan, driven by strong growth in Australia and North America. The company plans to accelerate its North American market presence in FY26.

Pacific Edge reports steady demand for its Cxbladder cancer diagnostic tests despite losing Medicare coverage and transitioning US customers to a new test. The company is advancing clinical evidence and a $21 million capital raise to support growth and regain coverage.

Anax Metals has mutually withdrawn its arbitration against a cornerstone investor over exclusive marketing rights, keeping its convertible notes valid and avoiding immediate financial disruption.

SportsHero Limited has inked major partnerships with leading Southeast Asian telcos, including a US$1 million contract with the Philippines’ PLDT, to expand its cloud-based gaming platform across the region.

Codeifai Limited (ASX – CDE) has agreed to acquire Antenna Transfer, an AI-driven quantum-secure platform, marking a strategic expansion into next-generation digital security. The deal positions Codeifai at the forefront of quantum-resilient infrastructure for high-security industries.

Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.

Adherium Limited has announced a partially underwritten entitlement offer aiming to raise approximately A$4.5 million through the issuance of new shares and options at a significant discount. The capital raise is designed to accelerate patient onboarding and product development for its respiratory monitoring technology.

Patriot Battery Metals has initiated work programs to unlock tantalum as a high-value by-product at its Shaakichiuwaanaan lithium project in Quebec, which ranks among the world’s top five tantalum pegmatite resources. Initial testwork shows promising recovery potential using conventional methods without impacting lithium extraction.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.